Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Name: Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Uploaded: 2025-11-29T14:00:00+0000
Duration: 3534 s
Description: Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00) SERD Monotherapy (13:34) SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)

Posted on 11/29/2025

58:54 |

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)
SERD Monotherapy (13:34)
SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)
SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)

CME information and select publications